ArticleAntimicrobial agents and chemotherapy2019
Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Review
- Refractory versus resistant invasive aspergillosis.The Journal of antimicrobial chemotherapy · 2025Review
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Intrinsic resistance to short-tailed azoles in the basal fungusFrontiers in microbiology · 2025Article
- Comparison of Morphological, Virulence, and Antifungal Susceptibility Characteristics WithinInfection and drug resistance · 2025Article
- Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches.Journal of fungi (Basel, Switzerland) · 2024Review
- Fungi involved in rhinosinusitis in arid regions: insights from molecular identification and antifungal susceptibility.Microbiology spectrum · 2023Article
- The Molecular Identification and Antifungal Susceptibility of Clinical Isolates ofMicroorganisms · 2023Article
- IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.Journal of fungi (Basel, Switzerland) · 2023Article
- Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology · 2023Review
- A Whole Genome Sequencing-Based Approach to Track down Genomic Variants in Itraconazole-Resistant Species ofJournal of fungi (Basel, Switzerland) · 2022Article
- Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.The Journal of antimicrobial chemotherapy · 2022Review
- Isavuconazole for COVID-19-Associated Invasive Mold Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- Review
- Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response.BMC infectious diseases · 2021Article
- Dissection of the Activity of Agricultural Fungicides against ClinicalJournal of fungi (Basel, Switzerland) · 2021Article
- Molecular typing of clinical and environmental Aspergillus fumigatus isolates from Iran using microsatellites.Current medical mycology · 2021Article
- Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.Frontiers in microbiology · 2021Review
- Emergence of Triazole Resistance inCurrent fungal infection reports · 2021Review
- PDR TransporterFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antifungal resistance is one of the major causes of the increasing mortality rates for fungal infections, especially for those caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.